With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.
Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.
As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.
When Robert A. Winn was named director of the University of Illinois Cancer Center in 2015, he knew that the skills required to be a successful cancer center director were very different from the skills he drew upon to be a successful scientist. So, he formed an informal, personal mentorship team.
Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.
In the last three years of her life, Andrea Werblin Reid wrote 150 poems on living with ovarian cancer and end of life. Werblin Reid died of ovarian cancer in 2022. Her third collection of poetry, “To See Yourself As You Vanish,” will be published Sept. 9.
Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
